<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733587</url>
  </required_header>
  <id_info>
    <org_study_id>GX-I7-CA-005</org_study_id>
    <nct_id>NCT03733587</nct_id>
  </id_info>
  <brief_title>GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors</brief_title>
  <official_title>A Phase 1b Study of GX-I7 in Combination With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b study to explore the safety and efficacy of GX-I7 in combination with CPA
      in patients with metastatic or recurrent solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b study to explore the safety and efficacy of GX-I7 in combination with CPA
      in patients with metastatic or recurrent solid tumors.

      This is 4 dose levels and increase dose level after confirm DLT of the previous dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2018</start_date>
  <completion_date type="Actual">May 13, 2020</completion_date>
  <primary_completion_date type="Actual">April 2, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of DLT</measure>
    <time_frame>within cycle 1(28days)</time_frame>
    <description>Incidence of nature of DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and characteristics of AE</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Incidence, nature and severity of adverse events graded according to NCI CTCAEv4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 6 months</time_frame>
    <description>ORR defined as complete response (CR) or partial response (PR) per RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of ADAs</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Incidence of anti-drug antibodies (ADAs) during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of GX-I7</measure>
    <time_frame>up to cycle 3 day 1(approximately 8 weeks)</time_frame>
    <description>Serum concentration of GX-I7 at specified timepoints for the Area under the concentration time-curve (AUC)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamide and GX-I7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide and determined dose of GX-I7 of each cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-I7</intervention_name>
    <description>GX-I7 25mg/ml/vial</description>
    <arm_group_label>Cyclophosphamide and GX-I7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 500mg/vial</description>
    <arm_group_label>Cyclophosphamide and GX-I7</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological confirmation of solid tumor, for which no standard therapy exists or is
             available any longer.

          -  Aged ≥19 years(Korean age).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Life expectancy ≥12 weeks.

          -  Adequate hematological and end organ function defined by the following

          -  laboratory results obtained within 14 days prior to Cycle 1 Day 1 (C1D1)

          -  Female subjects of childbearing potential (including a female who has undergone tubal
             ligation) requires a negative serum pregnancy test performed within 14 days prior to
             C1D1.

          -  Have an evaluable lesion(s) by Response Evaluation Criteria in Solid Tumors (RECIST)
             v1.1

          -  Subjects to be enrolled in the Phase 2a stage must be able to provide pre-treatment
             tissue biopsy or archival tissue and must have a tumor lesion.

          -  Providing the signed informed consent form (ICF).

        Exclusion Criteria:

          -  Unable to adhere to the study procedures and follow-up procedures.

          -  Pregnant or lactating subjects.

          -  Have alcoholic or other hepatitis, liver cirrhosis, or genetic liver disease.

          -  Have uncontrolled type 2 diabetes mellitus.

          -  Have history of a major surgery within 28 days prior to C1D1 or are anticipated to
             require a major surgery during the study.

          -  Have an evidence of severe or uncontrolled systemic disease, uncontrolled
             hypertension.

          -  Have received any other investigational or approved anticancer therapy within 3 weeks
             prior to C1D1.

          -  With a positive result of human immunodeficiency virus (HIV) infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minkyu Heo</last_name>
    <role>Study Director</role>
    <affiliation>Genexine_clinical team</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

